For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$1,196.03
Thesis
Eli Lilly markets the tirzepatide products Mounjaro and Zepbound, which target type 2 diabetes and obesity. As a diversified pharmaceutical company, it also advances an oral GLP-1 pipeline alongside its injectable franchise.
Catalysts
- Oral GLP-1 candidate clinical readouts
- Manufacturing capacity expansion for tirzepatide
- Label expansions for Mounjaro and Zepbound
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 24Trial initiationClinicalTrials.gov
Phase 3 trial (NCT07213804) initiated for Sofetabart Mipitecan in platinum-resistant/sensitive ovarian cancer; recruiting status.
- Jul 23Trial initiationClinicalTrials.gov
Phase 3 trial NCT07035093 of Retatrutide (LY3437943) in obesity/overweight with chronic low back pain status updated to ACTIVE_NOT_RECRUITING.
- Jul 22Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial (NCT06672939) of Orforglipron in adolescents with obesity or overweight with comorbidities; status recruiting.
- Jul 20Trial initiationClinicalTrials.gov
Phase 3 trial (NCT06439277) of tirzepatide in adolescents with obesity and comorbidities begins recruiting.
- Jul 20Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial NCT07157774 of Muvalaplin for major CV events in adults with elevated Lp(a); status recruiting.
- Jul 20OtherClinicalTrials.gov
Eli Lilly Phase 3 TRIUMPH-Outcomes retatrutide CV/kidney outcomes trial status updated to ACTIVE_NOT_RECRUITING (NCT06383390).
- Jul 20Trial initiationClinicalTrials.gov
Eli Lilly phase 2 master protocol trial NCT06143956 (obesity/overweight) status updated to RECRUITING
- Jul 20Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial (NCT06672939) of orforglipron in adolescents with obesity or overweight with comorbidities; status recruiting.